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OBJECTIVES We sought to determine whether the development of left ventricular hypertrophy (LVH) can
be demonstrated during adulthood in genetically affected relatives with hypertrophic
cardiomyopathy (HCM).
BACKGROUND Hypertrophic cardiomyopathy is a heterogeneous cardiac disease caused by mutations in nine
genes that encode proteins of the sarcomere. Mutations in cardiac myosin-binding protein C
(MyBPC) gene have been associated with age-related penetrance.
METHODS To further analyze dormancy of LVH in patients with HCM, we studied, using echocardi-
ography and 12-lead electrocardiography, the phenotypic expression caused by MyBPC
mutations in seven genotyped pedigrees.
RESULTS Of 119 family members studied, 61 were identified with a MyBPC mutation, including 21
genetically affected relatives (34%) who did not express the HCM morphologic phenotype (by
virtue of showing normal left ventricular wall thickness). Of these 21 phenotype-negative
individuals, 9 were children, presumably in the prehypertrophic phase, and 12 were adults. Of
the 12 adults with normal wall thickness #12 mm (7 also with normal electrocardiograms),
5 subsequently underwent serial echocardiography prospectively over four to six years. Of
note, three of these five adults showed development of LVH in mid-life, appearing for the
first time at 33, 34 and 42 years of age, respectively, not associated with outflow obstruction
or significant symptoms.
CONCLUSIONS In adults with HCM, disease-causing MyBPC mutations are not uncommonly associated
with absence of LVH on echocardiogram. Delayed remodeling with the development of
LVH appearing de novo in adulthood, demonstrated here for the first time in individual
patients with prospectively obtained serial echocardiograms, substantiates the principle of
age-related penetrance for MyBPC mutations in HCM. These observations alter prevailing
perceptions regarding the HCM clinical spectrum and family screening strategies and further
characterize the evolution of LVH in this disease. (J Am Coll Cardiol 2001;38:315–21)
© 2001 by the American College of Cardiology
Hypertrophic cardiomyopathy (HCM) is a familial cardiac
disease with heterogeneous clinical and phenotypic expres-
sion (1,2), caused by mutations in nine genes that encode
proteins of the cardiac sarcomere (3–9). In genetically
affected individuals in the present study group, HCM was
due to a mutation on chromosome 11p11.2, where the
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cardiac myosin-binding protein C (MyBPC) gene is en-
coded (7,8). Myosin-binding protein C contributes to the
structural integrity of the sarcomere by binding to the
myosin heavy chain and the cytoskeleton protein titin (7,8).
A clinical diagnosis of HCM is made by using two-
dimensional echocardiography, with the morphologic phe-
notype characterized by a variety of patterns of left ventric-
ular hypertrophy (LVH) in the presence of a nondilated left
ventricular (LV) chamber (1,2,10). Usually, hypertrophy is
absent or only mildly expressed until adolescence, at which
time LV wall thickness often increases substantially, achiev-
ing its mature morphologic state only after full growth and
maturation at ;17 to 18 years of age (11), with little further
increase in wall thickness during adulthood (12).
However, for the MyBPC mutant gene, retrospective
cross-sectional analysis has suggested that penetrance of the
phenotype may be age-related, with appearance often de-
layed until adulthood (7). We have focused on the pheno-
typic expression of MyBPC in HCM, and present, for the
first time, prospectively obtained, serial echocardiographic
evidence for the development of LVH in genetically affected
adults.
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METHODS
Selection of pedigrees and clinical investigation. Of the
13 families from the Minneapolis Heart Institute genotyped
in collaboration with the Department of Genetics at
Brigham and Women’s Hospital, seven proved to have
mutations in the MyBPC gene. Closely related relatives of
each proband at risk of inheriting the disease gene under-
went a cardiovascular examination before genotyping, in-
cluding 12-lead electrocardiography and two-dimensional
echocardiography with Doppler imaging. Serial echocardio-
grams were obtained in five genetically affected adult family
members in whom the initial echocardiographic study at
.25 years of age showed normal LV wall thickness; seven
other relatives who met these criteria did not agree to have
serial echocardiographic studies. Genetic and selected clin-
ical data from some patients were included in a previous
report (7).
Identification of mutations in the cardiac MyBPC gene.
As previously described (7), we obtained 5 to 30 ml of
peripheral blood from each proband, and deoxyribonucleic
acid (DNA) was isolated. The entire sequence of cardiac
MyBPC is in the GenBank data base (accession no.
U91629). Exons 2 through 35, which encode protein
sequences, were amplified from genomic DNA by using
primers designed from intron sequences. Genomic DNA
fragments amplified with the polymerase chain reaction
were purified with the QIAquick PCR purification kit
(QIAGEN, Santa Clarita, California) to remove residual
primers and were sequenced with the ABI PRISM dye-
terminator cycle-sequencing kit (Perkin-Elmer, Norwalk,
Connecticut).
Diagnostic clinical studies. Echocardiographic studies
were performed with Hewlett-Packard (Andover, Massa-
chusetts) nos. 500 and 2000 instruments. Images were
obtained in multiple cross-sectional planes using standard
transducer positions (10). The extent and distribution of
LVH were assessed from echocardiographic images, and the
site of maximal wall thickness was identified (10). Other
cardiac dimensions were measured from M-mode echocar-
diograms consistent with previous recommendations (13).
Peak instantaneous LV outflow gradient was estimated with
continuous wave Doppler echocardiography under basal
conditions (10).
Analysis of echocardiograms and electrocardiograms.
Echocardiograms and electrocardiograms (ECGs) were in-
terpreted prospectively by one experienced observer (B.J.M.)
who had no advance knowledge of the DNA diagnosis
made in the laboratory or previous clinical findings. In
selected instances, repeat echocardiograms were unavoid-
ably interpreted with some knowledge of the clinical cir-
cumstances.
Definition of HCM. The HCM phenotype was defined,
using echocardiography, as a hypertrophied nondilated LV
in the absence of another cardiac or systemic disease capable
of producing a comparable magnitude of LVH (14). For
adult family members ($18 years old), maximal wall thick-
ness $13 mm in one or more regions of the LV (in the
absence of body surface area correction) was used as an
arbitrary but conventional (7,10,12) clinical cut-off value to
designate LVH. For children ,18 years old, LVH was
defined as maximal wall thickness 6 2 SD, relative to body
surface area, age and gender (14). Twelve-lead ECG ab-
normalities were not used as the sole criterion for HCM
diagnosis, although ECG alterations may precede the ap-
pearance of LVH on the echocardiogram (15,16).
RESULTS
Genetic studies. The study group includes 119 surviving
family members in seven MyBPC pedigrees, studied with
two-dimensional echocardiography, 12-lead electrocardiog-
raphy and DNA analysis. Before this investigation, 14 other
relatives died of HCM (including 2 with the MyBPC
mutant gene), and 14 died of other cardiac or noncardiac
causes.
The MyBPC mutations were identified in 61 (51%) of
the 119 surviving relatives. Specific mutations identified
were insertions (Ins18bp1163 [17] and InsG791 [7], mis-
sense mutations (Arg495Gln [7] and Arg326Gln [unpub-
lished data]) and truncations (Int8DSG11A, IntDSG11T
and Int33DSG11A). These genetic studies confirmed pre-
viously recognized (and clinically evident) HCM in 15
children or adults (including the 7 probands).
Subjects without the HCM phenotype. At the time of
genotyping, of the 61 relatives with MyBPC mutations, 21
(34%) did not have morphologic evidence of the HCM
phenotype, with normal LV wall thickness in each segment.
Nine of these 21 individuals were #18 years of age and were
judged to probably be in the prehypertrophic phase of their
disease (11); each was asymptomatic.
The 12 remaining family members with the mutant
MyBPC gene (25% of the 48 genetically affected adults) are
particularly noteworthy because they were .25 years old
and showed normal LV wall thickness (#12 mm) at the
time of genotyping (mean age 38.9 6 13 years [range 26 to
62], 8 women and 4 men). Maximal LV thickness in these
12 relatives was 8 to 12 mm. Only one had systolic anterior
motion (SAM) of the mitral valve, mild in degree, and with
no evidence of outflow obstruction; LV end-diastolic cavity
Abbreviations and Acronyms
DNA 5 deoxyribonucleic acid
ECG 5 electrocardiogram or electrocardiographic
HCM 5 hypertrophic cardiomyopathy
LV 5 left ventricle or left ventricular
LVH 5 left ventricular hypertrophy
MyBPC 5 myosin-binding protein C
SAM 5 systolic anterior motion
316 Maron et al. JACC Vol. 38, No. 2, 2001
Development of LVH in Adults With HCM August 2001:315–21
dimensions were within normal limits (mean 44 6 4 mm
[range 38 to 56]).
In 7 of these 12 adults, the ECG was within normal
limits, but one or more ECG alterations were evident in the
remaining 5 individuals, including T-wave inversion and
left-axis deviation (n 5 2 each) and abnormal Q-waves, left
atrial enlargement and decreased R-waves in leads V1 and V2
(n 5 1 each). Two of the 12 genotype-positive/phenotype-
negative relatives represent examples of incomplete penetrance
of the HCM phenotype in which that family member was an
obligatory gene carrier (Fig. 1).
Development of LVH in adulthood. In 5 of the 12
genetically affected adults with normal LV wall thickness at
the time of genotyping, one to four additional echocardio-
grams were obtained three to six years later (Table 1). Two
of these five relatives (Patient nos. 4 and 5 in Table 1)
showed no measurable change in LV wall thickness over this
period.
However, of note, the remaining three patients (Patient
nos. 1 to 3 in Table 1) demonstrated substantial increases in
wall thickness of 6 to 7 mm (change of 55% to 64%). These
spontaneous hypertrophic changes and the development of
the HCM phenotype during adulthood occurred by 33 to 42
years of age in the presence of a nondilated LV chamber and
were not associated with the development of outflow ob-
struction under basal conditions, significant cardiac symp-
toms or systemic hypertension (Figs. 2 and 3).
One of the three adult relatives who developed LVH
showed marked changes in wall thickness during pregnancy
(Patient no. 2 in Table 1 and Fig. 2). Another had an
enlarged and elongated mitral valve (18) producing a mod-
erate degree of SAM (preferentially of the posterior leaflet)
(19), as the initial and sole clinically overt manifestation of
the mutant gene at the first echocardiographic evaluation
(Patient no. 1 in Table 1 and Fig. 3). One of these three
adults with morphologic conversion had a normal ECG and
two had abnormal ECG patterns at the time of their initial
echocardiogram (when hypertrophy was absent) these
ECGs showed little change in pattern as LV wall thickness
increased, although greater precordial T-wave inversion was
evident in one subject.
Phenotype penetrance. At genotyping, penetrance of the
MyBPC phenotype (i.e., LVH) appeared to be age-related
when assessed across all decades of life in a cross-sectional
analysis. In genetically affected relatives, identification of the
HCM phenotype by echocardiography increased with age.
Left ventricular hypertrophy was less frequent in relatives
,20 years old (4 [31%] of 13) and most common in those
.50 years (15 [83%] of 18). Furthermore, genetically
affected family members without LVH were relatively com-
mon among adults 20 and 39 years old (i.e., 15 [35%] of 23).
Subjects with the HCM phenotype. At genotyping, 40
(66%) of the 61 relatives with MyBPC mutations showed
characteristic morphologic evidence of the HCM pheno-
type, with increased LV wall thickness in one or more wall
segments. Most were adults (n 5 36; mean age 44 6 11
years [range 28 to 72]), but four were children (1 to 12 years
old). Of these 40 relatives, 26 (65%) were male, 15 (38%)
were symptomatic (including 7 with moderate to severe
symptoms) and 6 (15%) had SAM of the mitral valve, but
without evidence of basal outflow obstruction by Doppler
imaging.
Maximal LV wall thickness was 7 to 33 mm (20 6 5 mm
in adults; 12.5 6 4 mm in children), most prominently
involving the anterior ventricular septum (n 5 34), posterior
septum (n 5 3) or anterolateral free wall (n 5 3). Left
ventricular hypertrophy diffusely involved the septum and
LV free wall in 14 subjects, only the anterior and posterior
Figure 1. This myosin-binding protein C (MyBPC) pedigree shows generational skipping of the hypertrophic cardiomyopathy (HCM) phenotype. Note
that the adult woman (II.2) without left ventricular hypertrophy (LVH) on the echocardiogram (the 12-lead electrocardiogram was also normal) was,
nevertheless, the offspring of a father with LVH and the HCM mutant gene (I.2) and also passed the HCM gene to a son with LVH (III.4); a genetically
affected sister also has HCM with LVH (II.3). Circles 5 females; squares 5 males; solid symbols 5 genetically affected relatives with LVH (representing
HCM phenotype); open symbols 5 genetically affected relatives without LVH; stippled symbols 5 family members in whom clinical and genetic status
was undetermined. The presence (1) or absence (2) of the MyBPC mutation is indicated for persons in whom deoxyribonucleic acid was tested for the
mutation segregating in their family.
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septa in 16, and was confined to the anterior septum in 10.
There was no relationship between the particular MyBPC
mutation and distribution of LVH.
The 12-lead ECG showed a variety of abnormal patterns
associated with the morphologic HCM phenotype in 31
relatives (75%), most commonly T-wave inversion (n 5 18),
deep Q-waves (n 5 9) and increased precordial voltages
(n 5 8). Normal ECG patterns, however, were present in
10 (25%) of the 40 relatives.
DISCUSSION
Previous studies. Clinical studies (i.e., without laboratory
DNA analysis) have suggested that absence of echocardio-
graphically detectable LVH by the time mature growth and
development are achieved (age 17 to 18 years) signifies that
a mutation causing HCM is probably absent (11,12). Such
clinical judgments have generally proved reasonable in the
context of most HCM mutant genes, because virtually
complete penetrance of the phenotype (i.e., LVH) is usually
evident by the end of the accelerated adolescence growth
period (11,12).
Figure 2. Development of hypertrophic cardiomyopathy (HCM) pheno-
type in adulthood. Stop-frame two-dimensional echocardiograms at end-
diastole, at the papillary muscle level in the parasternal short-axis plane,
from a woman with familial HCM at age 27 years, when genotyping was
initiated (A), and at age 33 years, after myosin-binding protein C mutation
was known (B). (A) Left ventricular (LV) thickness is normal (#12 mm)
in all segments of the wall, including the ventricular septum (VS). (B) Six
years later, at age 33, wall thickness was abnormally increased (19 to
20 mm) in the anterior ventricular septum (AVS) and posterior septum
(PVS), as well as the anterolateral free wall (AFW). Mild mitral valve
systolic anterior motion (without septal contact or outflow gradient)
appeared at this time, although it is not shown here. Calibration marks are
10 mm apart.
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Age-related penetrance. However, as present data con-
firm, this basic clinical tenet does not necessarily apply to
MyBPC gene mutations (nor to some troponin T muta-
tions) for which penetrance of the HCM morphologic
phenotype may be incomplete in adults (5,7,20,21). Indeed,
fully 25% of our genetically affected adult family members
had normal echocardiograms at the time of genotyping.
This observation, as well as the fact that the MyBPC gene
is not uncommonly responsible for HCM (7–9,20), suggests
that there may well be many individuals affected by MyBPC
(but without LVH) who will escape clinical detection.
De novo remodeling in adults with MyBPC. In this
regard, our prospectively obtained, serial echocardiographic
observations have documented, for the first time, that de
novo LV remodeling may occur during the adult years, with
genetically affected individuals (previously without LVH)
spontaneously developing increased wall thickness charac-
teristic of HCM. Hence, we have demonstrated that the
dormant prehypertrophic phase of HCM can extend well
into mid-life in genetically affected individuals who, for
some reason, do not experience the substantial increase in
LV wall thickness usually associated with adolescence (11).
Rapid progression of LVH during young adulthood over
relatively short periods also suggests the possibility that an
environmental factor may have triggered the hypertrophic
response. The phenotypic heterogeneity of HCM is under-
lined by the fact that one of our young adults who developed
LVH had (before developing hypertrophy) an elongated and
enlarged mitral valve (18,19) producing moderate SAM of
the mitral valve, as the initial and sole clinically overt
evidence of HCM.
Development of LVH in adult patients with serial
follow-up represents an important clinical observation for
three reasons. First, demonstration of the initial develop-
ment of LVH during adulthood (by prospective serial
echocardiographic studies in the same patients) substanti-
ates, in a definitive fashion, the phenomenon of age-related
prevalence and late-onset hypertrophy in MyBPC, which
had previously been hypothesized indirectly from retrospec-
tive, cross-sectional analyses (7). Second, delayed appear-
ance of hypertrophy in adulthood may itself be clinically
relevant and have an effect on risk stratification by reassign-
ing selected asymptomatic individuals to higher risk cate-
gories, such as those with extreme wall thickening (22) in
whom treatment for prevention of sudden death may be
considered (23). Third, our observations are particularly
relevant to family screening strategies. In the absence of
DNA analysis, family members with normal echocardio-
grams at the time of their full growth and maturation
(usually ;18 years of age) can no longer be reassured
unequivocally that they do not carry a mutant gene for
HCM. This situation may necessitate further echocardio-
graphic studies in adulthood in selected clinical circum-
stances. Therefore, we believe that our present observations
modify the prevailing concepts about HCM and alter
clinical practice.
Study limitations. Although demonstration of spontane-
ous, de novo development of LVH in adults with HCM is
novel, we have presently identified only a small number of
such individuals with this form of disease progression.
Therefore, these cases do not provide evidence for the
frequency of adult morphologic conversions, but neverthe-
less establish the important principle that this process does
Figure 3. Development of hypertrophic cardiomyopathy (HCM) pheno-
type in adulthood. Echocardiograms from a man with familial HCM at age
29 years, when genotyping was initiated (A,C), and at age 35 years, after
the MyBPC mutation was known (B). (A) Parasternal long-axis view at
end-diastole, showing normal thickness of the ventricular septum (VS)
(i.e., 11 mm) and elongated mitral valve (MV) leaflets. (B) Six years after
the initial echocardiogram, the long-axis view at end-diastole shows, in
addition to greatly elongated MV leaflets, hypertrophy of the anterior basal
septum (arrows), which bulges prominently into the left ventricular (LV)
outflow tract. (C) Apical four-chamber view from the initial echocardio-
gram with normal LV wall thickness, showing only a moderate degree of
systolic anterior motion (arrow) produced preferentially by the distal
portion of the posterior mitral leaflet (as the sole and initial clinical
evidence of HCM); the anterior mitral leaflet (AmL) coapts abnormally at
the base of the posterior leaflet, rather than at its tip. Calibration marks are
10 mm apart. Ao 5 aorta; LA 5 left atrium; RV 5 right ventricle.
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in fact occur. Certainly, such structural remodeling
throughout adulthood in family members with previously
normal echocardiograms has proved extremely difficult to
document, given the many years (even decades) over which
serial echocardiographic studies would have to be performed
(2). Furthermore, we believe that such examinations per-
formed routinely would be unproductive in the vast majority
of individuals (most of whom would not carry a mutant
gene) and also create the unnecessary psychological impres-
sion of cardiac disease in many genetically unaffected indi-
viduals (9).
Clinical significance. At this preliminary stage of obser-
vation, the clinical significance that should be attached to
genotype-positive/phenotype-negative individuals with
MyBPC in families with HCM is unresolved. Indeed, with
the advent of preclinical genetic HCM diagnosis, many
more children and young adults will be identified as affected
with the disease, based solely on DNA analysis, and in the
absence of typical morphologic features. However, it should
be emphasized that the vast majority of adverse clinical
events occurring in HCM have been associated with pen-
etrance of the morphologic phenotype (i.e., LVH), and
usually in the context of substantial wall thickening
(1,2,22,23). Although the precise risk level associated with
the absence of LVH in genetically affected individuals is
largely unresolved, there is little evidence that such affected
individuals are predisposed to fatal cardiac events (24,25),
with the possible exception of a few selected families with
the cardiac troponin T gene (21). Therefore, management
of individuals with a mutant HCM gene in the absence of
hypertrophy requires restraint and prudence before adversely
influencing employment and educational opportunities (9)
or restricting lifestyle activities, such as competitive sports
(26).
Role of the 12-lead ECG. We found little evidence to
support the 12-lead ECG as superior to the echocardiogram
for clinical identification of adult family members with a
disease-causing mutation in the absence of hypertrophy
(27,28). In this regard, normal ECG patterns were present
in almost 60% of our genetically affected adults without
LVH (and even 25% of those adults with the HCM
phenotype). Nevertheless, the ECG has some clinical utility
as a supplemental test to raise the suspicion of HCM in
selected individuals without LVH (particularly children),
i.e., consistent with the previous observation in nongeno-
typed families that ECG patterns are often abnormal in
children with HCM during their prehypertrophic phase
(15). Furthermore, two of our three adult relatives with de
novo development of LVH had ECG alterations before the
appearance of hypertrophy (one with a clearly abnormal
ECG pattern), and including a patient with an enlarged and
elongated mitral valve as the only morphologic marker of
the mutant gene (18).
Conclusions. This report represents the first clinical doc-
umentation that the HCM phenotype may develop de novo
in adults. These novel observations regarding the spontane-
ous, rapid onset of LVH delayed to mid-life (i.e., adult
morphologic conversions) were derived in the context of
individual patient profiles obtained prospectively by serial
echocardiography. Such findings expand the HCM disease
spectrum and underline potential diagnostic and manage-
ment dilemmas raised by genetically affected family mem-
bers without the morphologic HCM phenotype. These data
alter our clinical perceptions of HCM and emphasize the
power and utility of laboratory DNA diagnosis for patients
affected by this complex disorder.
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